Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IELSG 34 everolimus in relapsed or refractory marginal zone lymphoma
2009-011725-14Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in marginal zone B-cell lymphoma (MZL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoints: Overall response rate and Safety. Started Mar 2010; status: completed.
02
Drugs
everolimus
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2009-011725-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011725-14.